Warning: The NCBI web site requires JavaScript to function. more...
Hypoxia and oxidative stress. Tumour hypoxia--therapeutic considerations.
Williams KJ, Cowen RL, Stratford IJ.
Breast Cancer Res. 2001;3(5):328-31. Epub 2001 Aug 7. Review.
Related citations
Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis.
Knowles HJ, Harris AL.
Breast Cancer Res. 2001;3(5):318-22. Epub 2001 Jul 17. Review.
Hypoxia and breast cancer: prognostic and therapeutic implications.
Lundgren K, Holm C, Landberg G.
Cell Mol Life Sci. 2007 Dec;64(24):3233-47. Review.
Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications.
Vaupel P, Briest S, Höckel M.
Wien Med Wochenschr. 2002;152(13-14):334-42. Review.
Hypoxia targeting gene expression for breast cancer gene therapy.
Lee M.
Adv Drug Deliv Rev. 2009 Aug 10;61(10):842-9. Epub 2009 May 6. Review.
Analysis of the effects of exposure to acute hypoxia on oxidative lesions and tumour progression in a transgenic mouse breast cancer model.
Kalliomäki TM, McCallum G, Lunt SJ, Wells PG, Hill RP.
BMC Cancer. 2008 May 28;8:151.
Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia.
Barr MP, Bouchier-Hayes DJ, Harmey JJ.
Int J Oncol. 2008 Jan;32(1):41-8.
Targeting tumour hypoxia in breast cancer.
Milani M, Harris AL.
Eur J Cancer. 2008 Dec;44(18):2766-73. Epub 2008 Nov 5. Review.
Gene therapy approaches to enhance bioreductive drug treatment.
Cowen RL, Garside EJ, Fitzpatrick B, Papadopoulou MV, Williams KJ.
Br J Radiol. 2008 Oct;81 Spec No 1:S45-56. Review.
Progression and metastasis in a transgenic mouse breast cancer model: effects of exposure to in vivo hypoxia.
Kalliomäki TM, McCallum G, Wells PG, Hill RP.
Cancer Lett. 2009 Sep 8;282(1):98-108. Epub 2009 Apr 7.
Radiation and hypoxia inducible gene therapy systems.
Scott SD, Greco O.
Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):269-76. Review.
Transcriptional targeting of acute hypoxia in the tumour stroma is a novel and viable strategy for cancer gene therapy.
Ingram N, Porter CD.
Gene Ther. 2005 Jul;12(13):1058-69.
Impact of supervised gene signatures of early hypoxia on patient survival.
Seigneuric R, Starmans MH, Fung G, Krishnapuram B, Nuyten DS, van Erk A, Magagnin MG, Rouschop KM, Krishnan S, Rao RB, Evelo CT, Begg AC, Wouters BG, Lambin P.
Radiother Oncol. 2007 Jun;83(3):374-82. Epub 2007 May 25.
Regulation of a rat VL30 element in human breast cancer cells in hypoxia and anoxia: role of HIF-1.
Ameri K, Burke B, Lewis CE, Harris AL.
Br J Cancer. 2002 Nov 4;87(10):1173-81.
The role of hypoxia-activated prodrugs in cancer therapy.
Denny WA.
Lancet Oncol. 2000 Sep;1(1):25-9. Review.
Employing tumor hypoxia for oncolytic therapy in breast cancer.
Chun YS, Adusumilli PS, Fong Y.
J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):311-8. Review.
Endogenous and induced oxidative stress in multi-cellular tumour spheroids: implications for improving tumour therapy.
Khaitan D, Dwarakanath BS.
Indian J Biochem Biophys. 2009 Feb;46(1):16-24. Review.
A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy.
Post DE, Van Meir EG.
Oncogene. 2003 Apr 10;22(14):2065-72.
Targeting the molecular basis for tumour hypoxia.
Carroll VA, Ashcroft M.
Expert Rev Mol Med. 2005 Apr 15;7(6):1-16. Review.
Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours.
McNally VA, Patterson AV, Williams KJ, Cowen RL, Stratford IJ, Jaffar M.
Curr Pharm Des. 2002;8(15):1319-33. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on